UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 28, 2025
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)
66 Hudson Boulevard East, New York, New York 10001-2192
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE/27
New York Stock Exchange
2.875% Notes due 2029
PFE/29
New York Stock Exchange
3.250% Notes due 2032
PFE/32
New York Stock Exchange
3.875% Notes due 2037
PFE/37A
New York Stock Exchange
4.250% Notes due 2045
PFE/45
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes Nox
At October 29, 2025, 5,685,707,552 shares of the issuer s voting common stock were outstanding.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Comprehensive Income
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements of Equity
Condensed Consolidated Statements of Cash Flows
Notes to Condensed Consolidated Financial Statements
10
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
36
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
57
Item 4.
Controls and Procedures
57
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
57
Item 1A.
Risk Factors
57
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
58
Item 3.
Defaults Upon Senior SecuritiesN/A
Item 4.
Mine Safety DisclosuresN/A
Item 5.
Other Information
58
Item 6.
Exhibits
58
Signature
58
N/A = Not Applicable
DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 24, 2025 and August 25, 2024, and for U.S. subsidiaries is as of and for the three and nine months ended September 28, 2025 and September 29, 2024. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2024 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
Indicates calculation not meaningful or results are greater than 100%
2024 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2024
340B Program
340B Drug Pricing Program
3SBio
3SBio, Inc. and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd.
AbbVie
AbbVie Inc.
Abingworth
Abingworth LLP
ACIP
Advisory Committee on Immunization Practices
AI
artificial intelligence
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
Blackstone
Blackstone Life Sciences
BMSBristol-Myers Squibb Company
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
CMS
Centers for Medicare & Medicaid Services
CODMChief Operating Decision Maker
Comirnaty
Unless otherwise noted, refers to, as applicable, the current formulation of Comirnaty (COVID-19 Vaccine, mRNA) 2025-2026 Formula as well as all prior authorized or approved formulations of the vaccine, which was first authorized in the U.S. during December 2020 pursuant to an EUA.
COVID-19novel coronavirus disease of 2019
Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Central Europe, Canada, Australia, Eastern Europe, Scandinavian countries, South Korea, Finland and New Zealand
DMD
Duchenne muscular dystrophy
EMAEuropean Medicines Agency
Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe (excluding the Balkans), Africa, the Middle East and Turkey
EPS
earnings per share
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended September 28, 2025
GAAPU.S. Generally Accepted Accounting Principles
HaleonHaleon plc
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
HRR
homologous recombination repair
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSU.S. Internal Revenue Service
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
mCC
metastatic cervical cancer
mCRCmetastatic colorectal cancer
mCRPCmetastatic castration-resistant prostate cancer
mCSPCmetastatic castration-sensitive prostate cancer
MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations
MDLMulti-District Litigation
Medicare Part B
a medical insurance plan that helps cover medically necessary services, outpatient care, and preventative services for people with Medicare
Medicare Part D
a prescription drug coverage program for people with Medicare
MeridianMeridian Medical Technologies, Inc.
Metsera
Metsera, Inc.
Moody s
Moody s Ratings (formerly Moody s Investors Service)
mRNAmessenger ribonucleic acid
NDA
New Drug Application
nmCRPCnon-metastatic castration-resistant prostate cancer
nmCSPC
non-metastatic castration-sensitive prostate cancer
NSCLCnon-small cell lung cancer
OBBBA
One Big Beautiful Bill Act
ODToral disintegrating tablet
Ono
Ono Pharmaceutical Co., Ltd.
OTCover-the-counter
Paxlovid(a)
an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)
PC1Pfizer CentreOne
PharmaciaPharmacia LLC (formerly Pharmacia Corporation)
Pierre Fabre
Pierre Fabre Medicament SAS
PNIF
Pfizer Netherlands International Finance B.V. (a wholly-owned finance subsidiary of Pfizer)
Prevnar familyIncludes Prevnar 20/Prevenar 20 (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)
PsApsoriatic arthritis
QTDQuarter-to-date or three months ended
RArheumatoid arthritis
R&Dresearch and development
RSVrespiratory syncytial virus
S&PS&P Global (formerly Standard & Poor s)
SCD
sickle cell disease
SeagenSeagen Inc. and its subsidiaries
SECU.S. Securities and Exchange Commission
SI&A
Selling, informational and administrative expenses
Takeda
Takeda Pharmaceutical Company Limited
UCulcerative colitis
U.K.United Kingdom
U.S.United States
ViiVViiV Healthcare Limited
Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac
YTDYear-to-date or nine months ended
(a)Paxlovid has not been approved, but has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency use of Paxlovid is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, 21 U.S.C. 360bbb-3(b)(1) unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheet at www.covid19oralrx.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X (formerly known as Twitter) accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three Months EndedNine Months Ended
(MILLIONS, EXCEPT PER SHARE DATA)September 28,
2025September 29,
2024September 28,
2025September 29,
2024
Revenues:
Product revenues
$13,920 $15,417 $37,168 $38,731
Alliance revenues
2,298 1,900 6,684 6,140
Royalty revenues
436 384 1,170 992
Total revenues16,654 17,702 45,022 45,864
Costs and expenses:
Cost of sales(a)
4,172 5,263 10,795 11,942
Selling, informational and administrative expenses(a)
3,186 3,244 9,632 10,456
Research and development expenses(a)
2,546 2,598 7,231 7,787
Acquired in-process research and development expenses1,390 13 1,401 20
Amortization of intangible assets1,223 1,312 3,644 3,927
Restructuring charges and certain acquisition-related costs286 313 945 1,669
Other (income)/deductions net517 243 2,210 2,030
Income from continuing operations before provision/(benefit) for taxes on income3,334 4,715 9,162 8,033
Provision/(benefit) for taxes on income
(216)234 (264)393
Income from continuing operations3,550 4,481 9,427 7,640
Discontinued operations net of tax (8)25 4
Net income before allocation to noncontrolling interests3,550 4,473 9,452 7,644
Less: Net income attributable to noncontrolling interests9 8 33 23
Net income attributable to Pfizer Inc. common shareholders$3,541 $4,465 $9,419 $7,621
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders$0.62 $0.79 $1.66 $1.35
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
$0.62 $0.79 $1.66 $1.35
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
$0.62 $0.79 $1.65 $1.34
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
$0.62 $0.78 $1.65 $1.34
Weighted-average shares basic5,685 5,667 5,682 5,663
Weighted-average shares diluted5,714 5,705 5,710 5,699
(a)Exclusive of amortization of intangible assets.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months EndedNine Months Ended
(MILLIONS)September 28,
2025September 29,
2024September 28,
2025September 29,
2024
Net income before allocation to noncontrolling interests$3,550 $4,473 $9,452 $7,644
Foreign currency translation adjustments, net365 131 (66)200
Unrealized holding gains/(losses) on derivative financial instruments, net(1)(303)(396)41
Reclassification adjustments for (gains)/losses included in net income(a)
177 (175)(242)(334)
176 (477)(638)(293)
Unrealized holding gains/(losses) on available-for-sale securities, net(10)59 124 (17)
Reclassification adjustments for (gains)/losses included in net income(b)
(97)(6)(25)80
(107)54 100 63
Reclassification adjustments related to amortization of prior service costs and other, net(16)(27)(70)(83)
Reclassification adjustments related to curtailments of prior service costs and other, net(5)(2)(49)(2)
(21)(29)(119)(85)
Other comprehensive income/(loss), before tax413 (322)(723)(115)
Tax provision/(benefit) on other comprehensive income/(loss)45 (157)(492)(81)
Other comprehensive income/(loss) before allocation to noncontrolling interests$367 $(166)$(231)$(35)
Comprehensive income/(loss) before allocation to noncontrolling interests$3,917 $4,307 $9,221 $7,609
Less: Comprehensive income/(loss) attributable to noncontrolling interests4 (3)26 (2)
Comprehensive income/(loss) attributable to Pfizer Inc.$3,913 $4,310 $9,195 $7,611
(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions net.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)September 28,
2025December 31, 2024
(Unaudited)
Assets
Cash and cash equivalents$1,343 $1,043
Short-term investments13,641 19,434
Trade accounts receivable, net of allowance for doubtful accounts: 2025 $434; 2024 $438
14,260 11,463
Inventories11,468 10,851
Current tax assets3,855 3,314
Other current assets2,358 4,253
Total current assets46,924 50,358
Long-term investments2,137 2,228
Property, plant and equipment, net of accumulated depreciation: 2025 $17,505; 2024 $16,483
18,880 18,393
Identifiable intangible assets, net
51,324 55,411
Goodwill69,101 68,527
Noncurrent deferred tax assets and other noncurrent tax assets11,048 8,662
Other noncurrent assets9,317 9,817
Total assets$208,731 $213,396
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2025 $4,247; 2024 $3,747
$4,303 $6,946
Trade accounts payable5,024 5,633
Dividends payable 2,437
Income taxes payable3,799 2,910
Accrued compensation and related items3,036 3,838
Deferred revenues924 1,511
Other current liabilities19,509 19,720
Total current liabilities36,596 42,995
Long-term debt57,409 57,405
Pension and postretirement benefit obligations2,157 2,115
Noncurrent deferred tax liabilities2,467 2,122
Other taxes payable3,401 6,112
Other noncurrent liabilities13,605 14,150
Total liabilities115,635 124,899
Commitments and Contingencies
Common stock481 480
Additional paid-in capital94,248 93,603
Treasury stock(115,011)(114,763)
Retained earnings121,150 116,725
Accumulated other comprehensive loss(8,066)(7,842)
Total Pfizer Inc. shareholders equity92,801 88,203
Equity attributable to noncontrolling interests295 294
Total equity93,096 88,497
Total liabilities and equity$208,731 $213,396
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, June 29, 20259,620 $481 $94,053 (3,935)$(115,010)$117,609 $(8,438)$88,695 $317 $89,012
Net income
3,541 3,541 9 3,550
Other comprehensive income/(loss), net of tax
372 372 (5)367
Cash dividends declared, per share: $
Common stock
Noncontrolling interests (31)(31)
Share-based payment transactions 195 (2)(1)193 193
Other 5 5
Balance, September 28, 20259,621 $481 $94,248 (3,935)$(115,011)$121,150 $(8,066)$92,801 $295 $93,096
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, June 30, 20249,592 $480 $93,197 (3,925)$(114,757)$116,596 $(7,816)$87,700 $275 $87,975
Net income
4,465 4,465 8 4,473
Other comprehensive income/(loss), net of tax(155)(155)(10)(166)
Cash dividends declared, per share: $
Common stock
Share-based payment transactions 281 (3)(2)276 276
Other(1)
Balance, September 29, 20249,592 $480 $93,477 (3,926)$(114,760)$121,059 $(7,971)$92,286 $272 $92,558
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20259,593 $480 $93,603 (3,926)$(114,763)$116,725 $(7,842)$88,203 $294 $88,497
Net income
9,419 9,419 33 9,452
Other comprehensive income/(loss), net of tax(224)(224)(7)(231)
Cash dividends declared, per share: $0.86
Common stock(4,889)(4,889)(4,889)
Noncontrolling interests (31)(31)
Share-based payment transactions28 1 645 (9)(248)(105)293 293
Other 6 7
Balance, September 28, 20259,621 $481 $94,248 (3,935)$(115,011)$121,150 $(8,066)$92,801 $295 $93,096
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l
Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.
LossShare-
holders EquityNon-controlling interestsTotal Equity
Balance, January 1, 20249,562 $478 $92,631 (3,916)$(114,487)$118,353 $(7,961)$89,014 $274 $89,288
Net income
7,621 7,621 23 7,644
Other comprehensive income/(loss), net of tax(10)(10)(25)(35)
Cash dividends declared, per share: $0.84
Common stock (4,760)(4,760)(4,760)
Share-based payment transactions30 2 846 (10)(273)(155)420 420
Other(1)
Balance, September 29, 20249,592 $480 $93,477 (3,926)$(114,760)$121,059 $(7,971)$92,286 $272 $92,558
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
(MILLIONS)September 28,
2025September 29,
2024
Operating Activities
Net income before allocation to noncontrolling interests$9,452 $7,644
Discontinued operations net of tax25 4
Net income from continuing operations before allocation to noncontrolling interests9,427 7,640
Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:
Depreciation and amortization4,905 5,222
Asset write-offs and impairments864 1,080
Deferred taxes(1,700)(1,706)
Share-based compensation expense574 700
Benefit plan contributions in excess of expense/income(418)(466)
Other adjustments, net(353)(455)
Other changes in assets and liabilities, net of acquisitions and divestitures(6,944)(5,992)
Net cash provided by/(used in) operating activities6,356 6,023
Investing Activities
Purchases of property, plant and equipment(1,784)(1,992)
Purchases of short-term investments(10,308)(3,957)
Proceeds from redemptions/sales of short-term investments13,236 2,630
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(3,251)2,649
Purchases of long-term investments(215)(75)
Proceeds from redemptions/sales of long-term investments504 1,541
Proceeds from sales of investment in Haleon(a)
6,311 3,491
Other investing activities, net302 (13)
Net cash provided by/(used in) investing activities4,795 4,275
Financing Activities
Proceeds from short-term borrowings 8,175
Payments on short-term borrowings(2,199)(7,774)
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
(897)(2,590)
Proceeds from issuance of long-term debt3,687
Payments on long-term debt(3,750)(2,250)
Cash dividends paid(7,326)(7,132)
Other financing activities, net(415)(455)
Net cash provided by/(used in) financing activities(10,900)(12,026)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
36 (37)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents287 (1,765)
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,107 2,917
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,394 $1,152
Supplemental Cash Flow Information
Cash paid during the period for:
Income taxes
$3,671 $3,172
Interest paid
1,758 1,833
Interest rate hedges95 31
(a) See Note 7A.
See Accompanying Notes.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2024 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2024 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 24, 2025 and August 25, 2024, and for U.S. subsidiaries is as of and for the three and nine months ended September 28, 2025 and September 29, 2024.
We manage our commercial operations through three operating segments, each led by a single manager: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. See Note 13A.
B. New Accounting Standard Adopted in 2025
In the third quarter of 2025, we early adopted a new accounting standard which adds a scope exception to exclude from derivative accounting non-exchange-traded contracts with variables (referred to as underlyings ) that are based on operations or activities specific to one of the parties to the contract. This new scope exception may apply to certain R&D funding arrangements. When adopted early in an interim reporting period, application of the standard is required as of the beginning of the current annual reporting period. We had no contracts or embedded features that were accounted for as derivatives but are no longer accounted for as derivatives as a result of applying the new standard. The adoption of this new accounting standard had no impact to our condensed consolidated financial statements.
C. Revenues and Trade Accounts Receivable
Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)September 28,
2025December 31, 2024
Reserve against Trade accounts receivable, net of allowance for doubtful accounts
$2,148 $1,627
Other current liabilities:
Accrued rebates9,157 7,195
Other accruals625 972
Other noncurrent liabilities
1,009 1,029
Total accrued rebates and other sales-related accruals$12,940 $10,822
Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market, delinquency status, and customer type (high risk versus low risk and government versus non-government), and reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
During the three and nine months ended September 28, 2025 and September 29, 2024, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.
For additional information on our trade accounts receivable, see Note 1G in our 2024 Form 10-K.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 2. Research and Development and In-Licensing Arrangements
A. Research and Development Arrangements
Research and Development Funding Arrangement with Abingworth In September 2025, we entered into an arrangement with Abingworth under which we will receive up to a total of $200 million in 2025 through 2027 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. If successful, upon regulatory approval in the U.S. for the indication based on the applicable clinical trial, Abingworth will be eligible to receive an approval-based fixed milestone payment of up to $120 million payable to Abingworth over a period of approximately eighteen months. Following potential regulatory approval, Abingworth will be eligible to receive a combination of fixed milestone payments of up to $280 million in total based on achievement of certain levels of cumulative applicable net sales and payable to Abingworth over a period of approximately one year, as well as royalties based on mid-single digit percentage of the applicable net sales.
Research and Development Funding Arrangement with Blackstone In March 2025, we entered into an arrangement with Blackstone under which we will receive up to a total of $326 million in 2025 through 2028 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $277 million payable to Blackstone over a period of one to three years. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $897 million in total based on achievement of certain levels of cumulative applicable net sales and payable to Blackstone over a period of five to seven years.
For both of the above arrangements, the net present value of the approval-based milestone payments and sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Accretion of interest on the liabilities will be recognized as interest expense in Other (income)/deductions net.
B. In-Licensing Arrangement
In-Licensing Arrangement with 3SBio In July 2025, we completed an exclusive global, ex-China, in-licensing agreement with 3SBio, a leading Chinese biopharmaceutical company, for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and vascular endothelial growth factor, currently undergoing several clinical trials in China for NSCLC, mCRC, and gynecological tumors. Under the terms of the agreement, 3SBio received an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion as well as tiered double-digit royalties on sales of SSGJ-707, if approved. Additionally, the agreement provides Pfizer the option to extend the license to include exclusive development and commercialization rights to SSGJ-707 in China. In exchange for the option to the exclusive rights in China, we made an upfront payment to 3SBio of $100 million and, in the event the option is exercised, we would pay an option exercise fee of up to $50 million depending on future events. In connection with this transaction, we recorded a $1.35 billion charge in the third quarter of 2025 in Acquired in-process research and development expenses and presented it as a cash outflow from operating activities. We also made a $100 million equity investment in 3SBio.
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Realigning Our Cost Base Program
In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. In the second quarter of 2025, we identified additional productivity opportunities to further reduce costs primarily in SI&A, driven in large part by enhanced digital enablement, including automation and AI, and simplification of business processes.
We expect costs associated with these components of the program to be incurred through 2027 and to total approximately $4.7 billion, representing primarily cash expenditures for severance, implementation, exit, and digital enablement costs, as well as non-cash asset write downs of which $3.1 billion is associated with our Biopharma segment.
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Additionally, in connection with our efforts to simplify the structure and sharpen the focus of our R&D organization, in the first quarter of 2025, we expanded this program after having identified additional opportunities to drive improvements in productivity and operational efficiencies through enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment. The majority of these costs were recorded in the first quarter of 2025, with cash outlays expected primarily in 2025 and 2026.
We expect costs associated with all the components of this program to total approximately $5.3 billion of which $3.7 billion is associated with the Biopharma segment.
From the start of this program through September 28, 2025, we incurred total costs of $3.7 billion, of which $2.9 billion is associated with our Biopharma segment (including $2.6 billion of restructuring charges).
B. Manufacturing Optimization Program
In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is primarily focused on operational efficiencies, and we expect costs for this first phase to total approximately $1.4 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. From the start of this program through September 28, 2025, we incurred costs of $1.0 billion, substantially all of which is restructuring costs for our Biopharma segment. These costs were recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026.
C. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months EndedNine Months Ended
(MILLIONS)September 28,
2025September 29,
2024September 28,
2025September 29,
2024
Restructuring charges/(credits):
Employee terminations$124 $25 $360 $1,009
Asset impairments111 111 328 177
Exit costs
2 82 96 145
Restructuring charges/(credits)(a)
237 217 784 1,331
Transaction costs(b)
Integration costs and other(c)
49 96 162 333
Restructuring charges and certain acquisition-related costs286 313 945 1,669
Net periodic benefit costs/(credits) recorded in Other (income)/deductions net
(6)2 (74)7
Inventory write-offs recorded in Cost of sales
33 33
Additional depreciation asset restructuring recorded in our condensed consolidated statements of operations as follows(d):
Cost of sales3 6 10 11
Selling, informational and administrative expenses 2 5
Research and development expenses1 1
Total additional depreciation asset restructuring
4 8 11 16
Implementation costs recorded in our condensed consolidated statements of operations as follows(e):
Cost of sales26 30 72 95
Selling, informational and administrative expenses26 13 46 77
Research and development expenses53 33 116 66
Total implementation costs105 75 234 238
Total costs associated with acquisitions and cost-reduction/productivity initiatives$423 $398 $1,150 $1,930
(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $240 million for the three months ended September 28, 2025 (including charges of $117 million for our Manufacturing Optimization Program and charges of $107 million for our Realigning our Cost Base Program), (ii) charges of $451 million for the nine months ended September 28, 2025 (including charges of $669 million for our Realigning our Cost Base Program and credits of $295 million for our Manufacturing Optimization Program), (iii) charges of $141 million for the three months ended September 29, 2024 (primarily including charges for our Realigning our Cost Base Program) and (iv) charges of $1.2 billion for the nine months ended September 29, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program and credits of $69 million for our Realigning our Cost
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Base Program). For the nine months ended September 28, 2025 and September 29, 2024, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
(b)Represents external costs for banking, legal, accounting and other similar services.
(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
(d)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
The following summarizes the components and changes in restructuring accruals:
(MILLIONS)Employee
Termination
CostsAsset
Impairment
ChargesExit CostsAccrual
Balance, December 31, 2024(a)
$2,046 $ $74 $2,120
Provision
360 328 96 784
Utilization and other(b)
(724)(328)(15)(1,067)
Balance, September 28, 2025(c)
$1,682 $ $155 $1,836
(a)Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).
(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
(c)Included in Other current liabilities ($1.3 billion) and Other noncurrent liabilities ($532 million).
Note 4. Other (Income)/Deductions Net
Components of Other (income)/deductions net include:
Three Months EndedNine Months Ended
(MILLIONS)September 28,
2025September 29,
2024September 28,
2025September 29,
2024
Interest income$(138)$(116)$(437)$(374)
Interest expense652 783 1,960 2,352
Net interest expense(a)
514 668 1,523 1,977
Net (gains)/losses recognized during the period on equity securities(b)
(201)(446)94 (129)
Net periodic benefit costs/(credits) other than service costs(73)(102)(333)(311)
Certain legal matters, net(c)
191 45 755 422
Certain asset impairments(d)
260 577 349
Haleon equity method (income)/loss
(150) (102)
Other, net(e)
(174)227 (406)(177)
Other (income)/deductions net
$517 $243 $2,210 $2,030
(a)The decrease in net interest expense in the third quarter and first nine months of 2025 reflects (i) a decrease in interest expense primarily driven by a reduction in commercial paper outstanding and (ii) an increase in interest income due to a higher total average investment asset balance compared to 2024.
(b)The net losses in the first nine months of 2025 include, among other things, a net loss of $144 million related to our previous investment in Haleon, composed of unrealized losses of $1.0 billion, partially offset by $900 million in realized gains on the sales of our remaining investment in the first quarter of 2025.
(c)The third quarter of 2025 primarily includes certain product liability expenses. The first nine months of 2025 primarily include certain product liability and other legal expenses. The third quarter and first nine months of 2024 primarily included certain product liability expenses related to products discontinued and/or divested by Pfizer.
(d)The third quarter and first nine months of 2025 include an intangible asset impairment charge associated with our Biopharma segment of $260 million related to IPR&D associated with a Phase 3 study for inclacumab for the treatment of SCD, which reflects unfavorable clinical trial results. The first nine months of 2025 also include an intangible asset impairment charge of $210 million associated with our Biopharma segment for KRAS G12D, a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner. The first nine months of 2024 included a $240 million intangible asset impairment charge, associated with our Biopharma segment that represented IPR&D related to a Phase 3 study for the treatment of DMD, which reflected unfavorable clinical trial results.
(e)The first nine months of 2025 include, among other things, dividend income of $184 million from our investment in ViiV. The third quarter and first nine months of 2024 primarily included, among other things, a charge of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. The first nine months of 2024 also included, among other things, dividend income of $183 million from our investment in ViiV and a $150 million realized gain on the partial sale of our previous investment in Haleon in the first quarter of 2024.
13
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Additional information about the intangible assets that were impaired during 2025 follows:
Nine Months Ended
Fair Value(a)
September 28, 2025
(MILLIONS)AmountLevel 1Level 2Level 3Impairment
IPR&D(b), (c)
$590 $ $ $590 $353
Indefinite-lived licensing agreement(b)
210
Developed technology rights(b)
14
Total
$590 $ $ $590 $577
(a)The fair value amount is presented as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See Note 1E in our 2024 Form 10-K.
(b)Reflects intangible assets written down to fair value in 2025. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.
(c)See Note 9.
Note 5. Tax Matters
A. Taxes on Income from Continuing Operations
Our effective tax rate for continuing operations was (6.5)% for the third quarter of 2025, compared to 5.0% for the third quarter of 2024, and was (2.9)% for the first nine months of 2025, compared to 4.9% for the first nine months of 2024. The negative and lower effective tax rates for the third quarter and the first nine months of 2025, compared to the third quarter and the first nine months of 2024, were primarily due to a favorable change in the jurisdictional mix of earnings, the remeasurement of deferred tax liabilities due to the enactment of the OBBBA on July 4, 2025, and tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years.
We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The seventh annual installment was paid by its April 15, 2025 due date. The eighth and final annual installment is due April 15, 2026 and is reported in current Income taxes payable as of September 28, 2025. Our obligations may vary due to the availability of attributes such as foreign tax and other credit carryforwards or carrybacks.
See Note 5A in our 2024 Form 10-K for information on our cash paid for income taxes, net of refunds.
B. Tax Contingencies
We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.
The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. Tax years 2019-2022 are under audit. Tax years 2023-2025 are open but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2016.
See Note 5D in our 2024 Form 10-K.
14
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)
Components of Tax provision/(benefit) on other comprehensive income/(loss) include:
Three Months EndedNine Months Ended
(MILLIONS)September 28,
2025September 29,
2024September 28,
2025September 29,
2024
Foreign currency translation adjustments, net(a)
$34 $(50)$(338)$(7)
Unrealized holding gains/(losses) on derivative financial instruments, net(2)(65)(84)5
Reclassification adjustments for (gains)/losses included in net income
32 (42)(55)(68)
30 (107)(139)(63)
Unrealized holding gains/(losses) on available-for-sale securities, net(1)7 16 (2)
Reclassification adjustments for (gains)/losses included in net income
(12)(1)(3)10
(13)7 12 8
Reclassification adjustments related to amortization of prior service costs and other, net(4)(6)(17)(20)
Reclassification adjustments related to curtailments of prior service costs and other, net(1) (11)1
(5)(6)(28)(18)
Tax provision/(benefit) on other comprehensive income/(loss)
$45 $(157)$(492)$(81)
(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.
Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:
Net Unrealized Gains/(Losses)Benefit Plans
(MILLIONS)Foreign Currency Translation Adjustments(a)
Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)
Balance, January 1, 2025
$(7,984)$57 $(106)$191 $(7,842)
Other comprehensive income/(loss)(b)
279 (499)87 (91)(224)
Balance, September 28, 2025$(7,705)$(442)$(19)$99 $(8,066)
(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.
(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.
15
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 7. Financial Instruments
A. Fair Value Measurements
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:
September 28, 2025December 31, 2024
(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2
Financial assets:
Short-term investments
Equity securities with readily determinable fair value(a)
$2,390 $ $2,390 $7,848 $6,456 $1,392
Available-for-sale debt securities:
Government and agency non-U.S.
5,905 5,905 6,855 6,855
Government and agency U.S.
2,633 2,633 2,853 2,853
Corporate and other
1,586 1,586 1,173 1,173
10,123 10,123 10,881 10,881
Total short-term investments12,513 12,513 18,729 6,456 12,273
Other current assets
Derivative assets:
Interest rate contracts
2 2
Foreign exchange contracts
301 301 1,056 1,056
Total other current assets302 302 1,056 1,056
Long-term investments
Equity securities with readily determinable fair values(b)
1,176 1,176 1,246 1,246
Available-for-sale debt securities:
Government and agency non-U.S.
1 1
1 1
Total long-term investments1,176 1,176 1 1,246 1,246
Other noncurrent assets
Derivative assets:
Interest rate contracts
60 60 13 13
Foreign exchange contracts
56 56 447 447
Total derivative assets116 116 460 460
Insurance contracts(c)
978 978 875 875
Total other noncurrent assets1,093 1,093 1,335 1,335
Total assets$15,085 $1,176 $13,909 $22,366 $7,701 $14,665
Financial liabilities:
Other current liabilities
Derivative liabilities:
Interest rate contracts$10 $ $10 $28 $ $28
Foreign exchange contracts
387 387 217 217
Total other current liabilities397 397 245 245
Other noncurrent liabilities
Derivative liabilities:
Interest rate contracts216 216 397 397
Foreign exchange contracts
964 964 723 723
Total other noncurrent liabilities1,180 1,180 1,121 1,121
Total liabilities$1,577 $ $1,577 $1,366 $ $1,366
(a)Includes money market funds primarily invested in U.S. Treasury and government debt. As of December 31, 2024, short-term equity securities included our previous investment in Haleon of $6.5 billion. In the first quarter of 2025, we sold the remaining portion of our investment in Haleon for $6.3 billion.
(b)Long-term equity securities of $141 million as of September 28, 2025 and $133 million as of December 31, 2024 were held in restricted trusts for U.S. non-qualified employee benefit plans.
(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).
Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $57 billion as of September 28, 2025 and December 31, 2024. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $56 billion as of September 28, 2025 and $54 billion as of December 31, 2024.
The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant
16
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
as of September 28, 2025 and December 31, 2024. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.
B. Investments
Total Short-Term and Long-Term Investments
The following summarizes our investments by classification type:
(MILLIONS)September 28,
2025 December 31, 2024
Short-term investments
Equity securities with readily determinable fair values
$2,390 $7,848
Available-for-sale debt securities10,123 10,881
Held-to-maturity debt securities1,128 705
Total Short-term investments$13,641 $19,434
Long-term investments
Equity securities with readily determinable fair values(a)
$1,176 $1,246
Available-for-sale debt securities1
Held-to-maturity debt securities48 45
Private equity securities at cost(a)
690 719
Equity-method investments223 217
Total Long-term investments$2,137 $2,228
Held-to-maturity cash equivalents$235 $184
(a)Represent investments in the life sciences sector.
Debt Securities
Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:
September 28, 2025December 31, 2024
Gross Unrealized Maturities (in Years)
Gross Unrealized
(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1
to 5Over 5Amortized CostGainsLossesFair Value
Available-for-sale debt securities
Government and agency non-U.S.
$5,926 $2 $(23)$5,905 $5,905 $1 $ $6,970 $8 $(123)$6,855
Government and agency U.S.
2,633 2,633 2,633 2,853 2,853
Corporate and other1,586 1,586 1,586 1,179 (6)1,173
Held-to-maturity debt securities
Time deposits and other
911 911 867 10 33 697 697
Government and agency non-U.S.
501 501 496 5 237 237
Total debt securities$11,556 $2 $(24)$11,535 $11,486 $16 $33 $11,935 $8 $(129)$11,814
Any expected credit losses to these portfolios would be immaterial to our financial statements.
Equity Securities
The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date: